AR 46588/AR/NIAMS NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2004	3
2005	3
2006	4
2007	5
2008	2
2009	1
2010	2
2013	1
2014	1
2024	0

1

Biomarkers for systemic lupus erythematosus: a review and perspective.

Liu CC, Manzi S, Ahearn JM. Liu CC, et al. Curr Opin Rheumatol. 2005 Sep;17(5):543-9. doi: 10.1097/01.bor.0000174182.70159.22. Curr Opin Rheumatol. 2005. PMID: 16093831 Review.

2

Cell-bound complement activation products (CB-CAPs) as a source of lupus biomarkers.

Calano SJ, Shih PA, Liu CC, Kao AH, Navratil JS, Manzi S, Ahearn JM. Calano SJ, et al. Adv Exp Med Biol. 2006;586:381-90. doi: 10.1007/0-387-34134-X_25. Adv Exp Med Biol. 2006. PMID: 16893085 Review.

3

New advances in measurement of complement activation: lessons of systemic lupus erythematosus.

Liu CC, Manzi S, Danchenko N, Ahearn JM. Liu CC, et al. Curr Rheumatol Rep. 2004 Oct;6(5):375-81. doi: 10.1007/s11926-004-0012-5. Curr Rheumatol Rep. 2004. PMID: 15355750 Review.

4

Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus.

Manzi S, Navratil JS, Ruffing MJ, Liu CC, Danchenko N, Nilson SE, Krishnaswami S, King DE, Kao AH, Ahearn JM. Manzi S, et al. Arthritis Rheum. 2004 Nov;50(11):3596-604. doi: 10.1002/art.20561. Arthritis Rheum. 2004. PMID: 15529364 Free article.

5

Platelet C4d is associated with acute ischemic stroke and stroke severity.

Mehta N, Uchino K, Fakhran S, Sattar MA, Branstetter BF 4th, Au K, Navratil JS, Paul B, Lee M, Gallagher KM, Manzi S, Ahearn JM, Kao AH. Mehta N, et al. Stroke. 2008 Dec;39(12):3236-41. doi: 10.1161/STROKEAHA.108.514687. Epub 2008 Oct 16. Stroke. 2008. PMID: 18927458

6

Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.

Kao AH, Navratil JS, Ruffing MJ, Liu CC, Hawkins D, McKinnon KM, Danchenko N, Ahearn JM, Manzi S. Kao AH, et al. Arthritis Rheum. 2010 Mar;62(3):837-44. doi: 10.1002/art.27267. Arthritis Rheum. 2010. PMID: 20187154 Free PMC article.

7

Platelet C4d is highly specific for systemic lupus erythematosus.

Navratil JS, Manzi S, Kao AH, Krishnaswami S, Liu CC, Ruffing MJ, Shaw PS, Nilson AC, Dryden ER, Johnson JJ, Ahearn JM. Navratil JS, et al. Arthritis Rheum. 2006 Feb;54(2):670-4. doi: 10.1002/art.21627. Arthritis Rheum. 2006. PMID: 16447243 Free article.

8

Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus.

Tripi LM, Manzi S, Chen Q, Kenney M, Shaw P, Kao A, Bontempo F, Kammerer C, Kamboh MI. Tripi LM, et al. Arthritis Rheum. 2006 Jun;54(6):1928-39. doi: 10.1002/art.21889. Arthritis Rheum. 2006. PMID: 16729301 Free article.

9

Genetic variation in the paraoxonase-3 (PON3) gene is associated with serum PON1 activity.

Sanghera DK, Manzi S, Minster RL, Shaw P, Kao A, Bontempo F, Kamboh MI. Sanghera DK, et al. Ann Hum Genet. 2008 Jan;72(Pt 1):72-81. doi: 10.1111/j.1469-1809.2007.00400.x. Epub 2007 Sep 25. Ann Hum Genet. 2008. PMID: 17900266

10

Mannose-binding lectin is a disease-modifying factor in North American patients with systemic lupus erythematosus.

Piao W, Liu CC, Kao AH, Manzi S, Vogt MT, Ruffing MJ, Ahearn JM. Piao W, et al. J Rheumatol. 2007 Jul;34(7):1506-13. Epub 2007 Jun 15. J Rheumatol. 2007. PMID: 17610319

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

19 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year